TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) in the fourth quarter compared to a -3.70% return for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84% (gross) and 13.88% (net) compared to 8.66% for the index. Global equity markets ended the quarter on a positive note, with Europe leading, followed by Emerging Markets. In most markets, large caps outperformed small caps. The trade truce between the United States and China was prolonged for an additional year, but global geopolitical concerns, whether related to tariffs or not, persisted. Third-quarter GDP exceeded expectations, but consumer caution persists due to ongoing labor-market softening, influencing the Fed’s decision on interest rate cuts. Please review the Strategy’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is an American company that sources and distributes pharmaceutical products. On March 19, 2026, Cencora, Inc. (NYSE:COR) stock closed at $331.74 per share. One-month return of Cencora, Inc. (NYSE:COR) was -8.13%, and its shares gained 24.05% over the past 52 weeks. Cencora, Inc. (NYSE:COR) has a market capitalization of $64.534 billion.
TimesSquare Capital U.S. Focus Growth Strategy stated the following regarding Cencora, Inc. (NYSE:COR) in its fourth quarter 2025 investor letter:
“Our preferred Health Care stocks are companies that provide novel therapies for unmet needs and command premium pricing, or specialized service providers. Cencora, Inc. (NYSE:COR), a pharmaceutical sourcing and distribution company, gained 8%. Fiscal fourth-quarter earnings outpaced consensus estimates, with strength in the U.S. offsetting a miss in international business. Management also announced that it is considering strategic alternatives for the animal health and non-core parts of its PharmaLex business.”
Cencora, Inc. (NYSE:COR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Cencora, Inc. (NYSE:COR) at the end of the fourth quarter, up from 59 in the previous quarter. In the first quarter of fiscal 2026, Cencora, Inc.’s (NYSE:COR) consolidated revenue increased 5.5% year-over-year to $85.9 billion due to solid growth in both reportable segments. While we acknowledge the risk and potential of Cencora, Inc. (NYSE:COR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Cencora, Inc. (NYSE:COR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Cencora, Inc. (NYSE:COR) and shared a list of best healthcare stocks to buy for 2026. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
